Last reviewed 2026-05-27 · How we verify

Topical TA-102 D

Sun Pharmaceutical Industries, Inc. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Topical TA-102 D is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 1 development.

Topical TA-102 D is not mentioned in the provided facts, so I will provide a summary based on the available information. Topical TA-102 formulations are being studied in an open-label trial to assess their efficacy and potential for adrenal suppression in subjects with plaque psoriasis. The study involves three different topical formulations: TA-102 A, TA-102 B, and TA-102 C.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Topical TA-102 D
Sponsor	Sun Pharmaceutical Industries, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open-Label Study to Assess Safety (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Topical TA-102 D CI brief — competitive landscape report
Topical TA-102 D updates RSS · CI watch RSS
Sun Pharmaceutical Industries, Inc. portfolio CI

Frequently asked questions about Topical TA-102 D

What is Topical TA-102 D?

Topical TA-102 D is a Small molecule drug developed by Sun Pharmaceutical Industries, Inc..

Who makes Topical TA-102 D?

Topical TA-102 D is developed by Sun Pharmaceutical Industries, Inc. (see full Sun Pharmaceutical Industries, Inc. pipeline at /company/sun-pharmaceutical-industries-inc).

What development phase is Topical TA-102 D in?

Topical TA-102 D is in Phase 1.

Manufacturer: Sun Pharmaceutical Industries, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing